January 3, 2024 03:06 PM ESTUpdated January 4, 04:47 AM

Dr. Reddy's, Torrent Pharma and Laurus Synthesis all land Form 483 letters following FDA inspections

Anna Brown

News Reporter

In December the FDA hit India-based Torrent Pharmaceuticals, Laurus Synthesis and Dr. Reddy’s Laboratories each with Form 483 letters published on Dec. 28. This was …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dr. Reddy's, Torrent Pharma and Laurus Synthesis all land Form 483 letters following FDA inspections

Anna Brown

News Reporter

Sign up to read this article for free.

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Dr. Red­dy's, Tor­rent Phar­ma and Lau­rus Syn­the­sis all land Form 483 let­ters fol­low­ing FDA in­spec­tions

Anna Brown

News Reporter

Sign up to read this article for free.

more like this

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Dr. Reddy's, Torrent Pharma and Laurus Synthesis all land Form 483 letters following FDA inspections

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL